|
| Effect evaluation of Diyu Shengbai Tablet on elevating leukocytes in patients with lung cancer undergoing chemotherapy and its impact on quality of life |
| Hits 7 Download times 7 Received:August 24, 2024 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2024.11.11 |
| Key Words
Diyu Shengbai Tablet;chemotherapy;lung cancer patient;leukocyte;quality of life |
| Author Name | Affiliation | E-mail | | LIU Nian | Tianjin Chest Hospital, Tianjin 300222, China | | | QIN Jianwen | Tianjin Chest Hospital, Tianjin 300222, China | | | LI Wei | Tianjin Chest Hospital, Tianjin 300222, China | | | XU Junhui | Tianjin Chest Hospital, Tianjin 300222, China | gaogaogao2000@163.com |
|
| Abstract
|
| [Objective] To evaluate the effect of Diyu Shengbai Tablets on improving leukocytes and quality of life in patients with lung cancer after chemotherapy. [Methods] The 126 lung cancer patients with chemotherapy treated in Tianjin Chest Hospital from January to April 2024 were selected for the study. Using a randomized controlled trial,126 patients with lung cancer chemotherapy were divided into trial group and control group,with 63 patients in each group. The trial group received Diyu Shengbai Tablet during conventional chemotherapy with 0.75 g a time,3 times a day for 4 weeks. Control patients were treated with conventional chemotherapy. Both two groups received other conventional treatments and received nutritional support. During the test,the blood test index was reviewed every week,and recorded the change of leukocyte level. The change of leukocyte values,neutrophils,incidence of myelosuppression and quality of life were compared between the two groups. [Results] The test group had significantly more leukocytes and neutrophils than those in the control group,with a statistically significant difference(P<0.05). After treatment,the incidence of myelosuppression was significantly lower than that in the control group,with a statistically significant difference(P<0.05). The total effective rate of the trial group was 95.24%,The control group's total effective rate was 80.95%. The difference between the two groups was statistically significant(P<0.05). The trial group patients showed significantly better comprehensive scores in five dimensions of quality of life(emotional,physiological,social/family,functional,and related symptoms) compared to the control group,with statistical significance(P<0.05). [Conclusion] Diyu Shengbai Tablet can effectively improve the number of leukocytes and neutrophils in patients with lung cancer undergoing chemotherapy,antagonize the side effects of bone marrow suppression,and improve the quality of life of patients. |
|
|
|
|
|
|
|
